Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Liver disease and erythropoietic protoporphyria: a concise review.
[erythropoietic protoporphyria]
The
porphyries
are
a
group
of
metabolic
disorders
characterized
by
deficiencies
in
the
activity
of
enzymes
involved
in
the
biosynthesis
of
heme
.
In
erythropoietic
protoporphyria
(
EPP
)
,
in
the
majority
of
cases
an
autosomal
dominant
disease
,
there
is
a
mutation
of
the
gene
that
encodes
ferrochelatase
(
FECH
)
.
FECH
deficiency
is
associated
with
increased
concentrations
of
protoporphyrin
in
erythrocytes
,
plasma
,
skin
and
liver
.
The
prevalence
of
this
inherited
disorder
oscillates
between
1
:
75
000
and
1
:
200
000
.
Clinical
manifestations
of
EPP
appear
in
early
infancy
upon
first
exposure
to
the
sun
.
Nevertheless
,
approximately
5
%
-
20
%
of
patients
with
EPP
develop
liver
manifestations
.
Retention
of
protoporphyrin
in
the
liver
is
associated
with
cholestatic
phenomena
and
oxidative
stress
that
predisposes
to
hepatobiliary
disease
of
varying
degrees
of
severity
,
such
as
cholelithiasis
,
mild
parenchymal
liver
disease
,
progressive
hepatocellular
disease
with
end-
stage
liver
disease
and
acute
liver
failure
.
Liver
damage
is
the
major
risk
in
EPP
patients
,
so
surveillance
and
frequent
clinical
and
biochemical
liver
follow-up
is
mandatory
.
The
diagnostic
approach
consists
in
detecting
increased
levels
of
protoporphyrin
,
decreased
activity
of
FECH
and
genetic
analysis
of
the
FECH
gene
.
A
variety
of
non-surgical
therapeutic
approaches
have
been
adopted
for
the
management
of
EPP
associated
with
liver
disease
,
but
none
of
these
has
been
shown
to
be
unequivocally
efficacious
.
Nevertheless
,
some
may
have
a
place
in
preparing
patients
for
liver
transplantation
.
Liver
transplantation
does
not
correct
the
constitutional
deficiency
of
FECH
.
Consequently
,
there
is
a
risk
of
recurrence
of
liver
disease
after
liver
transplantation
as
a
result
of
continuing
overproduction
of
protoporphyrin
.
Some
authors
recommend
that
bone
marrow
transplantation
should
be
considered
in
liver
allograft
recipients
to
prevent
recurrence
of
hepatic
disease
.
Diseases
Validation
Diseases presenting
"but none of these has been shown to be unequivocally efficacious"
symptom
erythropoietic protoporphyria
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom